The news of Needham analyst David Saxon reiterating a Buy rating on Staar Surgical and maintaining a $75 price target is positive for the company. This reaffirms the analyst's confidence in the company's growth potential and could lead to increased investor interest, potentially driving the stock price up in the short term.